Skip to content

Rafael Holdings, Inc. RFL Health Care — Goodwill

Similar metrics at other companies

Huron Consulting Group logo
HURNHealthcare — Goodwill recorded in connection with business acquisitions(1)
$0
Huron Consulting Group logo
HURNHealthcare — Goodwill
$511.6M+12.8%
Procter & Gamble logo
PGHealth Care — Goodwill
$7.9B+3.0%
ExlService Holdings logo
EXLSHealthcare and Life Sciences — Goodwill
$189.57M0.0%
Globe Life logo
GLHealth — Goodwill
$180.84M0.0%
Webster Financial Corporation logo
WBSHealthcare Financial Services — Goodwill
$316.07M

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s health care — goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s health care — goodwill?
Rafael Holdings, Inc. (RFL) reported health care — goodwill of $19.94M in Q1 2026.
How has Rafael Holdings, Inc.'s health care — goodwill changed year-over-year?
Rafael Holdings, Inc.'s health care — goodwill decreased by 29.5% year-over-year, from $28.28M to $19.94M.
What does health care — goodwill mean?
This metric represents the intangible asset value recorded when the company acquires a health care business for a price exceeding the fair market value of its identifiable net assets. It reflects the premium paid for expected synergies, brand reputation, and intellectual property within the oncology and pharmaceutical research segment. Monitoring this balance is essential for assessing potential impairment risks related to the company's clinical-stage investments.